Schizophrenia is a prototypical network disorder with widespread brain-morphological alterations, yet it remains unclear whether these distributed alterations robustly reflect the underlying network layout. We tested whether large-scale structural alterations in schizophrenia relate to normative structural and functional connectome architecture, and systematically evaluated robustness and generalizability of these network-level alterations. Leveraging anatomical MRI scans from 2439 adults with schizophrenia and 2867 healthy controls from 26 ENIGMA sites and normative data from the Human Connectome Project (n = 207), we evaluated structural alterations of schizophrenia against two network susceptibility models: (i) hub vulnerability, which examines associations between regional network centrality and magnitude of disease-related alterations; (ii) epicenter mapping, which identifies regions whose typical connectivity profile most closely resembles the disease-related morphological alterations. To assess generalizability and specificity, we contextualized the influence of site, disease stages, and individual clinical factors and compared network associations of schizophrenia with that found in affective disorders. Our findings show schizophrenia-related cortical thinning is spatially associated with functional and structural hubs, suggesting that highly interconnected regions are more vulnerable to morphological alterations. Predominantly temporo-paralimbic and frontal regions emerged as epicenters with connectivity profiles linked to schizophrenia's alteration patterns. Findings were robust across sites, disease stages, and related to individual symptoms. Moreover, transdiagnostic comparisons revealed overlapping epicenters in schizophrenia and bipolar, but not major depressive disorder, suggestive of a pathophysiological continuity within the schizophrenia-bipolar-spectrum. In sum, cortical alterations over the course of schizophrenia robustly follow brain network architecture, emphasizing marked hub susceptibility and temporo-frontal epicenters at both the level of the group and the individual. Subtle variations of epicenters across disease stages suggest interacting pathological processes, while associations with patient-specific symptoms support additional inter-individual variability of hub vulnerability and epicenters in schizophrenia. Our work outlines potential pathways to better understand macroscale structural alterations, and inter- individual variability in schizophrenia.
- MeSH
- dospělí MeSH
- konektom * metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie * metody MeSH
- mladý dospělý MeSH
- mozek patologie patofyziologie MeSH
- mozková kůra patologie patofyziologie MeSH
- nervová síť patologie patofyziologie diagnostické zobrazování MeSH
- nervové dráhy patofyziologie patologie MeSH
- schizofrenie * patologie patofyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mozek patologie MeSH
- prospektivní studie MeSH
- schizofrenie * MeSH
- senioři MeSH
- stárnutí MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
OBJECTIVE: Schizophrenia has recently been associated with widespread white matter microstructural abnormalities, but the functional effects of these abnormalities remain unclear. Widespread heterogeneity of results from studies published to date preclude any definitive characterization of the relationship between white matter and cognitive performance in schizophrenia. Given the relevance of deficits in cognitive function to predicting social and functional outcomes in schizophrenia, the authors carried out a meta-analysis of available data through the ENIGMA Consortium, using a common analysis pipeline, to elucidate the relationship between white matter microstructure and a measure of general cognitive performance, IQ, in patients with schizophrenia and healthy participants. METHODS: The meta-analysis included 760 patients with schizophrenia and 957 healthy participants from 11 participating ENIGMA Consortium sites. For each site, principal component analysis was used to calculate both a global fractional anisotropy component (gFA) and a fractional anisotropy component for six long association tracts (LA-gFA) previously associated with cognition. RESULTS: Meta-analyses of regression results indicated that gFA accounted for a significant amount of variation in cognition in the full sample (effect size [Hedges' g]=0.27, CI=0.17-0.36), with similar effects sizes observed for both the patient (effect size=0.20, CI=0.05-0.35) and healthy participant groups (effect size=0.32, CI=0.18-0.45). Comparable patterns of association were also observed between LA-gFA and cognition for the full sample (effect size=0.28, CI=0.18-0.37), the patient group (effect size=0.23, CI=0.09-0.38), and the healthy participant group (effect size=0.31, CI=0.18-0.44). CONCLUSIONS: This study provides robust evidence that cognitive ability is associated with global structural connectivity, with higher fractional anisotropy associated with higher IQ. This association was independent of diagnosis; while schizophrenia patients tended to have lower fractional anisotropy and lower IQ than healthy participants, the comparable size of effect in each group suggested a more general, rather than disease-specific, pattern of association.
- MeSH
- analýza hlavních komponent MeSH
- anizotropie MeSH
- bílá hmota diagnostické zobrazování MeSH
- dospělí MeSH
- faktorová analýza statistická MeSH
- inteligence * MeSH
- kognice fyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mozek diagnostické zobrazování MeSH
- nervové dráhy diagnostické zobrazování MeSH
- schizofrenie (psychologie) * MeSH
- schizofrenie diagnostické zobrazování patofyziologie MeSH
- studie případů a kontrol MeSH
- Wechslerovy škály MeSH
- zdraví dobrovolníci pro lékařské studie MeSH
- zobrazování difuzních tenzorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
The relationship between the use of some substances and aggressive behaviour is well established. The most convincing research to indicate this relationship comes from studies on alcohol use, and to a lesser extent on cocaine use. Despite the global prevalence of methamphetamine, few published works have examined the relationship between methamphetamine use and aggression. This presentation focuses on the clinical manifestations of methamphetamine use, and discusses how a group of methamphetamine users experi- ence and express anger and aggression. The results from a randomised controlled trial of cognitive behaviour therapy for methamphetamine use in relation to anger and aggression are presented. The use of methamphetamine as an expression of the self is discussed. Melissa Claire is a Psychologist whose work as a clinician has included providing treatment to substance users in a range of treatment set- tings and using a variety of treatment models. She has specialised in forensic psychology, providing treatment to adolescent offenders detained in juvenile prisons and post-release community care; as well as adult offenders in residential care. Her private practice work has focused on forensic assessment, reporting and expert witness testimony. Her teaching work has been in the areas of assessment and treatment of substance users, developmental psychology and addiction across the lifespan. Melissa has spent much of the past decade researching anger, aggression, violence and criminal behaviour in methamphetamine users. Her Ph.D. research examined associations between methamphetamine use, anger, aggression and violence, criminal behaviour and psychiatric distress among methamphetamine users attending treatment. Melissa's presentations discuss how anger and aggression are associated with the use and treatment of methamphetamine.
Clinical assessment is fundamental to providing an accurate and reliable diagnosis for the treatment of illness. One of the difficulties in understanding the relationship between substance use and aggression relates to how we measure anger and aggression. This presentation discusses the importance of understanding the experience and expression of anger as potential risk factors for methamphetamine use, psychiatric distress and criminal behaviour. This presentation describes how anger and aggression has been formally measured in methamphetamine users using Spielberger's STAXI-2. Benefits of conducting a formal assessment of anger and aggression, and how this can assist clinicians when treating methamphetamine users are examined. The need to develop a universal diagnostic classification of anger and aggression in order to develop clinically relevant thresholds and indicators for treatment success is also discussed.
